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A B S T R A C T
Remote ischemic conditioning (RIC) constitutes a promising method in which a tissue or organ is
exposed to intermittent ischemia/reperfusion periods enabling it to provide protection to a distant target
organ. RIC has been tested in various clinical settings through its simple application by means of
intermittent inﬂation of a blood pressure cuff placed on a limb, primarily evaluating its potential abilities
to decrease myocardial injury biomarkers. Its use on other organs, such as the kidneys or brain, has
recently been a topic of research. To date, no study has yet been powerful enough to reach a conclusion
on the potential beneﬁt of RIC on clinical outcomes. The future role of RIC in the clinical arena could be
clariﬁed by the large phase III trials currently underway targeting major outcomes as primary endpoints.
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While restoring blood ﬂow in a heart that is undergoing ischemia
is paramount to improving clinical outcome, the reperfusion process
itself can paradoxically induce irreversible cellular damage, referred reserved.
Fig. 1. Schematic representation of the targets of remote ischemic conditioning (RIC). This ﬁgure shows the potential targets of RIC in the ischemia/reperfusion context. Cycles
of brief inﬂation/deﬂation of a cuff placed on limb can be performed before ischemia (remote ischemic preconditioning, RIPC), during ischemia (remote ischemic
preconditioning, RIPerC), or after blood ﬂow restoration (remote ischemic postconditioning, RIPostC). I, ischemia induced by the blood pressure cuff inﬂation; R, reperfusion
by deﬂation of the blood pressure cuff.
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observed in several clinical settings, including cardiac surgery
[coronary artery bypass grafting (CABG), valvular replacement,
congenital heart repair], major vascular surgery (aortic aneurism
repair, carotid endarterectomy), percutaneous coronary interven-
tion (PCI), and organ transplantation. Despite the numerous
improvements that have been made in modern management
strategies for at-risk patients to reduce ischemia-related cardiac
damage, limiting myocardial reperfusion injury remains a challenge.
In 1986, Murry et al. described local ischemic preconditioning
(IPC) as a cardioprotective technique [2]. IPC consists of four cycles
of 5 minutes (min) of ischemia and 5 min reperfusion of the
circumﬂex artery before placing a sustained ligature, and the
technique was found to signiﬁcantly reduce myocardial damage in
dogs. Some years later, Zhao et al. reported similar beneﬁcial
effects when applying transient brief episodes of ischemia at the
time of reperfusion [3]. This ischemic postconditioning (IPostC)
technique has proven successful in patients with acute myocardial
infarction. Staat et al. were the ﬁrst to report that four cycles of 1-
min inﬂation and 1-min deﬂation of an angioplasty balloon,
initiated within 1 min of reopening the culprit coronary artery,
reduced infarct size by 34% [4]. Most of the clinical trials published
on this subject have demonstrated that IPostC can mitigate infarct
size [5]. Nevertheless, both IPC and IPostC require invasive
procedures that may present high risk in a clinical situation.
Remote ischemic conditioning (RIC) therefore represents a
particularly attractive alternative. First assessed within the heart
by Przyklenk et al. in 1993 [6], RIC is a conditioning strategy in
which an organ or tissue other than the target is exposed to brief
periods of I/R for conditioning. Given that it allows invasive
procedures to be avoided, the RIC technique using transient limb
ischemia as a stimulus has emerged as an intelligent strategy
choice for a wide range of clinical scenarios involving potential
ischemia-reperfusion insult [7].In this review, we present an overview of RIC-induced effects
and clinical perspectives in the heart and other organs.
RIC stimulus in humans
RIC offers a simple application consisting of intermittent
inﬂation of a blood pressure cuff or tourniquet placed on an
upper or lower limb. As with other strategies tested in local
ischemic conditioning, there have been various different RIC
regimens reported, as presented in Fig. 1. RIC stimulus can be
applied prior to the intervention at risk (remote preconditioning,
RIPC), during ischemia (remote perconditioning, RIPerC), or after
blood ﬂow restoration (remote postconditioning, RIPostC).
Clinical applications of RIC
Given how simple RIC is to perform, numerous clinical trials have
been launched to measure RIC-induced effects on myocardial injury
and, more recently, on the occurrence of cardiovascular events.
RIC in cardiac surgery
The ﬁrst attempt to translate RIC experimental ﬁndings to the
clinical arena was made by Gunaydin et al. in 2000, involving eight
patients undergoing scheduled CABG [8]. Their results were
mitigated due to the trial being clearly underpowered. Since then,
numerous trials involving cardiac surgery patients have been
conducted, as summarized in Online Table 1.
RIC in pediatric surgery
Cheung et al. produced successful results in 2006 when
evaluating RIC in 37 children undergoing congenital heart repair
[9]. Myocardial injury, assessed by troponin I release, was found to
be reduced after remote preconditioning of a lower limb applied in
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these results were later conﬁrmed, some reports have directly
contradicted them (Online Table 1). One explanation for the
differences is the inclusion of cyanotic heart, a condition where the
heart is submitted to chronic hypoxia that probably induced prior
preconditioning and limited the technique’s impact in clinical
investigations.
RIC in CABG surgery
In 2007, Hausenloy et al. conducted the ﬁrst sizeable trial
testing RIPC in 57 patients undergoing elective CABG, reporting a
43% reduction in the troponin T area under the curve (AUC)
compared to controls [10]. Many more trials have since been
conducted, along with several meta-analyses speciﬁcally analyzing
CABG results. Yetgin et al. included 891 CABG patients (13 trials) in
their review and demonstrated RIC to have an overall beneﬁcial
effect on myocardial injury biomarkers in this subgroup [11]. Their
ﬁndings revealed anesthetic agents (cardioprotection induced by
volatile agents) and the timing of RIC protocol to be confounding
factors. In terms of clinical events, Zhang et al. reported no
difference in their study in the impact on all-cause mortality at
30 days in eight studies [12]. In contrast, Thielmann et al. have
recently published the largest trial to date involving patients
undergoing CABG, which reported a decrease in mortality and
major adverse cardiac and cerebrovascular events (MACCEs) at
1 year with RIPC administered after anesthesia induction
[13]. Further studies are still necessary to assess the RIC effects
on MACCE occurrence. The ongoing ERRICA (ClinicalTrials.gov
Identiﬁer: NCT01247545) and RIPHeart-Study (NCT01067703)
trials will provide information on MACCEs as a composite primary
outcome in high-risk surgery patients undergoing CABG.
Valvular replacement and high-risk surgery
Few authors had evaluated RIC-induced effects in isolated
mitral valve replacement (VR) or combined surgery (CABG + VR)
with any success. Nevertheless, Hong et al. reported no differences
in MACCE outcomes after applying a remote preconditioning + -
postconditioning protocol in 1280 patients [14]. In addition, Young
et al. observed that cardiac biomarkers did not differ from controls
in 96 high-risk surgery patients, namely affected by prolonged
bypass time procedures or impaired left-ventricular function
[15]. This suggests a certain amount of uncertainty regarding the
efﬁciency of RIC in this particular setting and emphasizes the need
for further studies with standardized protocols.
RIC and percutaneous coronary intervention
RIC in primary PCI
ST-elevation myocardial infarction (STEMI) patients undergo-
ing urgent revascularization by PCI were investigated in ﬁve
randomized trials, which demonstrated that RIC appeared to
reduce myocardial infarct size, assessed by the following different
means: biomarkers, single photon emission computed tomogra-
phy (SPECT), and cardiac magnetic resonance (CMR), regardless of
which RIC protocol was used (per or postconditioning). Rentoukas
et al. were the ﬁrst to test the effect of RIPerC, evaluating
96 patients requiring urgent PCI and demonstrating a signiﬁcant
increase in full ST-segment resolution (primary endpoint) after RIC
and a non-signiﬁcant reduction in troponin peak [16]. In the Botker
et al. trial, where 333 patients were submitted to a remote
ischemic preconditioning protocol during ambulance transport,
RIC was found to increase median salvage index at 30 days
[17]. Crimi et al. studied 100 patients undergoing primary PCI for
anterior STEMI, reporting that when RIPostC was administered in
the ﬁrst minutes of reperfusion, after thrombectomy or balloon
inﬂation, infarct size was reduced by 20% [18]. Prunier et al. testedthe combination of local conditioning (IPostC) with an RIPerC
protocol administered immediately prior to revascularization and
demonstrated a 30% reduction in biomarker release after RIC, with
no additional beneﬁt provided by IPostC [19]. Finally, in a recent
study, White et al. conﬁrmed these results in 197 STEMI patients
(thrombolysis in myocardial infarction grade = 0 ﬂow) who
underwent RIPerC consisting of the inﬂation of a blood pressure
cuff 40 min before revascularization, reporting a 27% decrease in
infarct size, assessed by CMR, and a limitation of the extent of
myocardial edema in RIC patients [20].
RIC in elective PCI
Elective PCI, usually not associated with myocardial infarction,
does not share the same physiopathological mechanisms of
reperfusion injury as primary PCI. The results of elective PCI
studies are therefore more miscellaneous in nature (Online
Table 2), yet the Hoole et al. CRISP study did report positive
results for this context [21]. They demonstrated that RIC was
associated with a signiﬁcant reduction in troponin concentrations
(primary outcome) in 242 included patients, also providing some
evidence of its beneﬁcial effects on early clinical events (secondary
outcome). The long-term follow-up data were published by Davies
et al., reporting improved event-free survival rates 6 years after the
RIC protocol [22]. In contrast, two recent trials have reported that
RIPostC had no impact on myocardial injury biomarker reduction
[23,24], suggesting its use in this clinical situation to be of limited
interest. This ﬁnding was conﬁrmed by meta-analysis results.
Yetgin et al. [11] evaluated 557 patients undergoing all-type PCI
(four studies) and found that RIC did not reduce myocardial injury
on pooled analysis, yet proved effective if only considering primary
PCI.
RIC and major vascular surgery
There have only been six studies testing RIC in major vascular
surgery published to date (Online Table 3): ﬁve were trials in
abdominal aortic aneurism (AAA) repair, including four concerning
open AAA surgery and one endovascular repair, and the sixth was a
trial assessing carotid endarterectomy. Ali et al. were the ﬁrst to
report a reduction in myocardial injury and renal impairment after
administering RIPC to 42 patients admitted for AAA surgical repair
[25]. Li et al. conﬁrmed these positive results in pulmonary and
intestinal injury in 62 patients requiring infra-renal AAA repair
[26]. Nevertheless, other trials have reported conﬂicting results on
RIC, describing a lack of effect on neurological [27], renal [28,29],
and myocardial injury [30], as well as the occurrence of
cardiovascular events [27,29]. In 2011, Desai et al. performed
the only currently existing meta-analysis dedicated to RIC-induced
effects in vascular surgery, reporting a reduction in myocardial
infarction, although no difference was observed in perioperative
mortality, renal impairment or duration of hospital stay [31]. The
majority of these trials were pilot studies, however, using small
sample sizes and lacking the power needed to detect statistical
signiﬁcance. For these reasons, their results should be interpreted
carefully. The much larger-scope SAVES trial (NCT01691911) is
investigating whether RIC could reduce complications in patients
undergoing major vascular surgery.
The next step: RIC and protection of other organs
Renal protection
Zimmerman et al. were the ﬁrst to report a decrease in acute
kidney injury (AKI) after administering RIPC to 120 patients
undergoing cardiac surgery [32]. Deftereos et al. conﬁrmed these
results using remote postconditioning, consisting of four cycles of
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patients undergoing PCI [33]. RIC has also recently been tested in
contrast-medium induced nephropathy [34,35], exhibiting similar
beneﬁcial results, as well as in partial nephrectomy [36]. A recent
meta-analysis was published by Yang et al., investigating RIPC-
induced effects on renal function in 1334 patients scheduled for
cardiac or vascular interventions [37]. They reported observing a
trend of reduced AKI risk following sessions of RIPC, with no
difference observed in postoperative renal biomarker levels or in-
hospital mortality. Several trials are currently underway to
determine the potential RIC-induced beneﬁts for contrast-induced
acute kidney injury, namely the Re-DUCE-F trial (NCT02054858),
evaluating patients who require contrast-enhanced CT scans; the
‘‘remote ischemic preconditioning and risk of contrast-induced
acute kidney injury in patients undergoing coronary stent
implantation’’ trial (NCT01827891), involving patients undergoing
PCI; and the RenPro-Long trial (NCT01760031), investigating long-
term renal prognosis after RIPC. In addition, the renal protection
provided by RIC is also currently being investigated after partial
nephrectomy (NCT01771003), after trans-catheter valve implan-
tation (RenPro-TAVI; NCT01925235), and after peripheral angio-
plasty (NCT02054871).
Neuroprotection
Brain protection is a crucial goal in various relevant clinical
settings. Aneurysmal sub-arachnoid hemorrhage has been studied
in a number of phase I trials, which have reported good tolerance of
the RIC stimulus in these critically-ill patients [38,39]. One pilot
study has indicated promising neurological results with this
technique in cervical decompression surgery [40]. For stroke cases,
Hougaard et al. tested the combination of RIPerC with thromboly-
sis, reporting there to be no clear beneﬁt in terms of cerebral infarct
size at 1 month and functional recovery at 3 months [41]. In
contrast, Meng et al. described encouraging results when applying
bilateral upper-arm RIC, administered in two daily sessions, in
68 patients suffering from symptomatic intracranial artery
stenosis [42]. Larger trials are now required to provide further
information on RIC utility in this indication.
Solid organ transplantation
To date, only a small number of studies have evaluated the use
of RIC in the context of kidney transplant. In 2013, Chen et al.
conducted the ﬁrst clinical study testing remote preconditioning,
with a protocol of three 5-min cycles with a blood pressure cuff
encircling the leg, in 60 patients receiving living-donor renal
transplant [43]. The RIPC protocol was administered either to the
donor or recipient of the organ. The renal injury markers were not
found to differ between the groups. In 2014, Wu et al. conducted a
trial involving 48 recipients of kidney transplants from 24 cardiac-
death donors. The ﬁrst recipient was preconditioned by intermit-
tent clamping of the external iliac artery, with three 5/5-min
cycles, while the other received no preconditioning [44]. Their
results were promising, with proven renal function improvement
following RIPC, demonstrated by creatinin level decrease and
glomerular ﬁltration rate elevation, and a reduction in early
markers of renal ischemia-reperfusion injury, namely urine
neutrophil gelatinase-associated lipocalin. The REPAIR trial is
currently underway testing the effects of limb RIC applied to both
the kidney donor and recipient 24 h before transplant in
400 living-donor renal transplant patients (Current Controlled
Trials Identiﬁer: ISRCTN30083294). Another ongoing trial, CON-
TEXT, is currently investigating RIC on immediate and extended
kidney graft function in 200 enrolled patients (NCT01395719).
Recently, a small trial involving approximately 60 patientsundergoing bilateral sequential lung transplantation tested RIC-
induced effects on primary graft dysfunction, producing non-
signiﬁcant results [45].
Ongoing issues
The mechanisms of RIC
The precise mechanism through which RIC exerts its protection
is still unclear. RIC is believed to produce protective signals that are
conveyed from the remote tissue to the target organ [46]. Several
different mechanisms may be involved, including blood-borne
factor release [47], neuronal pathway activation [48], and systemic
response participation [49]. These protective signals can activate
intracellular survival signaling pathways in the target organ
[46]. Several studies have described endogenous factors to be
involved in protective mechanisms, such as bradykinin [50],
opioids [51], adenosine [52], erythropoietin [53], endocannabi-
noı¨ds [54], microvesicles [55], apolipoprotein A-I [56], and
microRNA [57]. One likely explanation is that RIC activates the
release of several circulating humeral factors and involves multiple
endogen protective mechanisms.
RIC-effect on clinical outcomes
While the meta-analysis reported RIC to have a beneﬁcial effect
in reducing the amount of myocardial injury assessed by
biomarkers (Online Table 4), the results on clinical outcomes
have so far not been clear. The occurrence of early events was
regularly mentioned as a secondary objective in several small-
sized clinical studies, yet these were not strongly-powered enough
to relate clinical outcomes. Moreover, the results were contradic-
tory among the studies. Two studies described seeing a reduction
in clinical events after applying RIC in elective PCI [21] and CABG
[13] cases, 30 days after intervention, yet the results from other
studies were much less enthusiastic [17,18,23,29,58]. Hong et al.
included 1280 patients undergoing elective cardiac surgery in their
trial and investigated MACCE occurrence as a composite primary
outcome [14], ﬁnding no signiﬁcant difference between the control
and RIPC groups. A recent trial conﬁrmed these results, demon-
strating a signiﬁcant reduction in perioperative myocardial injury
(26%) after RIPC in 180 patients undergoing elective CABG or valve
surgery, but with no difference observed in terms of clinical events
at 6 weeks [59]. On the other hand, long-term clinical events are
often not reported. To date, only three clinical trials have reported
beneﬁcial long-term follow-up results after RIC in three distinct
clinical settings. In their assessment of elective PCI, Davies et al.
published their 2013 long-term follow-up of the CRISP study,
which indicated a reduction in MACCE occurrence 6 years
following RIC [22]. Continuing on from Botker’s work in primary
PCI [17], Sloth et al. suggested RIC to have beneﬁcial long-term
effects 5 years after STEMI, reporting a reduction in MACCE
outcomes and all-cause mortality [60]. Thielmann et al. reported a
decrease in all-cause mortality over a year after RIPC in CABG
patients [13].
The results we obtained from published meta-analyses
suggested that RIC has a neutral effect on short-term MACCEs or
mortality, regardless of which clinical scenario was considered,
with the choice of cardiac surgery, CABG, or in wider indications. In
a recent publication, Healy et al. conﬁrmed these ﬁndings in a
speciﬁc meta-analysis focused on clinical event occurrence,
assessing 2200 patients requiring major cardiovascular surgery
[61]. No signiﬁcant difference was described in terms of
perioperative mortality, perioperative myocardial infarction,
cerebrovascular accident, new onset of arrhythmia requiring
medication, or hospital stay. It must be underlined that only the
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long-term follow-up being published more recently or still under
investigation. Therefore, further works are needed to determine
RIC-induced effects on major clinical outcomes.
Conclusion
RIC represents an attractive and harmless method for reducing
ischemia-reperfusion injury in various clinical settings. Its future
in the clinical arena will most deﬁnitely depend on the results of
the large ongoing phase III trials targeting major outcomes as
primary endpoints.
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